Business | 2009.11.04
Promedior Announces Publication of Preclinical Studies in Science Translational Medicine Demonstrating that hSAP Inhibits Kidney Fibrosis
MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies demonstrating that human Serum Amyloid P (hSAP) potently inhibited fibrosis in two independent model systems of kidney fibrosis. The study results indicate a potential role for hSAP in treating kidney diseases such as diabetic nephropathy and transplant nephropathy where
For more information, please visit
http://www.businesswire.com/news/home/20091104005202/en
